Law Firm Kirby McInerney LLP Investigating Potential Claims On Behalf Of Hi-Tech Pharmacal Co., Inc. Shareholders

Kirby McInerney LLP is investigating potential claims against the Board of Directors of Hi-Tech Pharmacal Co., Inc. (“Hi-Tech” or the “Company”) (NASDAQ:HITK) related to the proposed acquisition of the Company by Akorn, Inc. (“Akorn”). Under the terms of the agreement, Akorn will acquire all of the outstanding common stock of Hi-Tech for $43.50 per share in cash, for a total transaction value of approximately $640 million.

The investigation concerns whether the Hi-Tech Board of Directors violated their fiduciary duties in agreeing to the proposed transaction and whether the $43.50 per share consideration adequately values Hi-Tech shares.

If you are a Hi-Tech shareholder and wish to obtain additional information, please contact J. Brandon Walker, Esq. by email at, by telephone at (212) 699-1145 or (888) 529-4787, or by filling out this contact form.

Kirby McInerney LLP is a New York-based law firm concentrating in securities, shareholder, whistleblower, antitrust and consumer litigation. For additional information, please go to

Copyright Business Wire 2010

If you liked this article you might like

Stocks Plummet on Prospect of U.S.-Led Airstrike on Syria

The Deal: Akorn Acquires Hi-Tech Pharmacal for $540M

All is Not Well as Futures Sink on Syria, U.S. Debt Debate

5 Stocks Set to Soar on Bullish Earnings

Healthcare Sector: High Quality Stocks At A Great Value